Safety and efficacy of AMG 714 in patients with type 2 refractory coeliac disease: a phase 2a, randomised, double-blind, placebo-controlled, parallel-group studyChristophe Cellier, Ralph Raymond, Georgia Malamut et al.|The Lancet. Gastroenterology & hepatology|2019Cited by 101
616 - AMG 714 (Anti-IL-15 MAB) Halts the Progression of Aberrant Intraepithelial Lymphocytes in Refractory Celiac Disease type II (RCD-II): A Phase 2A, Randomized, Double-Blind, Placebo-Controlled Study Evaluating AMG 714 in Adult Patients with RCD-II/Pre-EATLChristophe Cellier, Chris J. Mulder, Gerd Bouma et al.|Gastroenterology|2018Cited by 10